Innovative biocompatible and biodegradable family of drug carrier that enables long lasting and pre-programmed release of therapeutic drugs. The patent protected technology enables to entrap a very large variety of one or more biologically active molecules, and to release them in a pre-programmed rate near their target. Following its administration, each type of the entrapped drugs is released according to the desired clinical rate, ranging from several days to several months. Deep bone infections are recurrently accounted for severe morbidity and disabilities, whereas the current solutions are frequently insufficient, expensive and highly toxic. Feasibility has been demonstrated in-vitro with different drugs as well as by the development of medical solutions intending to treat deep bone infections and periodontitis. 

Pre-clinical proof-of-concept in orthopedic applications of bone infections, addressing a large growing potential market.

Clinical studies are expected in Q211 and the product is expected to be approved by the regulatory path of a drug-device combination.
Polypid was founded with Xenia in 2008.

TEAM

Dr. Noam Emanuel, Ph.D., CEO, Co-Founder
Dr. Emanuel holds a Ph.D. degree from the faculty of medicine, the Hebrew University, Jerusalem, Israel. Dr. Emanuel's main experience is in the development of drug delivery systems and immunology. Dr. Emanuel is widely experienced in different biotechnological industrial projects in various areas including immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery and medical devices.

Dr. Shlomo Barak, Board Member, Co-Founder
Dental surgeon, graduated in the Hebrew University & "Hadassah" Jerusalem. Specialized in Oral & Maxillofacial Surgery. Director, Institute of Dentistry & Oral-Maxillofacial Surgery ,Hillel-Yaffe Medical Center, Hadera .Affiliated with the Rappaport Faculty of Medicine, The Technion, Haifa. Dr. Barak is an internationally-known oral and maxillofacial surgeon, lecturer and educator. Active in the field for more than 25 years.

Dr. Moshe Neuman, Board Member, Co-Founder
Periodontist, Private clinic limited to Periodontology and Dental Implants, D.M.D. and M.Sc. in Bone Biology from the Hebrew University in Jerusalem. Diplomate of the American Board of Periodontology and member in the American Academy of Periodontology. Specialized in Periodontology, University of Rochester - Eastman Dental Center, Rochester, NY.

Dr. Yafit Stark, Ph.D., Board Member
Vice President, Teva Pharmaceutical Industries, Ltd. Chief Clinical Officer and Head of Oncology, Emerging Therapeutic Areas and Biogenerics Innovative R&D.
Dr. Stark joined Teva in 1987. From 1991 to 1994 she was based in the US, where she established the Innovative R&D Division of Teva USA and was responsible for the clinical development of Copaxone®. Dr. Stark then established and managed the Innovative R&D Division's global clinical research and clinical development of all innovative products at Teva.
Dr. Stark holds a Ph.D. degree in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science.

Prof. Yechezkel Barenholz, Board Member
Prof. Barenholz is a recognized expert in the field of drug delivery. Prof. Barenholz is the co-inventor of DoxilTM, a liposomal formulation of doxorubicin for cancer treatment marketed in the USA by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). Prof. Barenholz serves as Head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry of the Hadassah Medical School at the Hebrew University of Jerusalem, Israel.

Prof. David Segal, Head of PolyPid's Scientific Advisory Board 
Formerly the head of Orthopedic Surgery Department, Hadassah Medical Center, Jerusalem, Israel and the Orthopedic Surgery, Boston University School of Medicine, Boston, MA.